Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Rzeszow – page 24

337 clinical trials in Rzeszow, Poland across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Rzeszow at a glance
337
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

337 trials in Rzeszow

Open in trial search

Chronic cutaneous lupus erythematosus

Not recruiting

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Type IIa hyperlipidaemia

Not recruiting

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Hormone-dependent prostate cancer

Not recruiting

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Type V hyperlipidaemia

Not recruiting

Study on Long-Term Safety and Efficacy of ARO-APOC3 for Adults with Mixed Dyslipidemia

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Small cell lung cancer

Not recruiting

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Asthma

Not recruiting

Study on the Effects of ARO-RAGE (ADS-015) for Patients with Inflammatory Lung Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ADS-015
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Rzeszow

What the registry says about research in the country

01 Inflammatory and Autoimmune Conditions

Ongoing research focusing on innovative treatments for inflammatory bowel diseases and autoimmune conditions, including studies on new therapies for ulcerative colitis and Crohn's disease.

  • Ulcerative Colitis
  • Crohn's Disease
  • Psoriasis
  • Atopic Dermatitis

Multiple trials evaluating novel compounds and biological therapies for inflammatory conditions.

02 Cardiovascular and Metabolic Research

Studies investigating treatments for heart failure prevention and metabolic disorders, with emphasis on innovative therapeutic approaches for obesity and cardiovascular health.

  • Heart Failure Prevention
  • Obesity Management
  • Chronic Kidney Disease

Focus on combination therapies and novel compounds for cardiometabolic conditions.

03 Neurological and Immune System Disorders

Clinical investigations targeting multiple sclerosis and chronic inflammatory conditions affecting the nervous system.

  • Multiple Sclerosis
  • CIDP
  • Immune System Diseases

Evaluation of new therapeutic agents for managing neurological and immune-mediated conditions.

04 Specialized Medical Conditions

Research on various specialized conditions including geographic atrophy and reproductive health treatments.

  • Age-Related Macular Degeneration
  • Contraceptive Studies
  • Pulmonary Conditions

Diverse studies focusing on improving patient outcomes across multiple therapeutic areas.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.